Literature DB >> 28711086

The new paradigm of systemic therapies for metastatic melanoma.

Virginia O Volpe1, Daniel M Klufas2, Upendra Hegde1, Jane M Grant-Kels3.   

Abstract

New treatments for metastatic melanoma work through distinct mechanisms: enhancing the immune response and blocking cellular proliferation. Agents that enhance the immune response include ipilimumab, pembrolizumb, and nivolumab; agents that block cellular proliferation include vemurafenib, dabrafenib, trametinib, cobimetinib, binimetinib, and selumetinib. The translational impact of laboratory discoveries has revolutionized management of metastatic melanoma and enhanced the prognosis of affected patients.
Copyright © 2017 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  immune therapy; metastatic melanoma; targeted therapy

Mesh：

Substances：

Year:  2017        PMID： 28711086     DOI： 10.1016/j.jaad.2017.04.1126

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN： 0190-9622            Impact factor:   11.527


  13 in total

Review 1.  Melanoma and Immune Checkpoint Inhibitors.

Authors:  Masutaka Furue; Takamichi Ito; Naoko Wada; Maiko Wada; Takafumi Kadono; Hiroshi Uchi
Journal:  Curr Oncol Rep       Date:  2018-03-23       Impact factor: 5.075

2.  Breslow Density Is a Novel Prognostic Feature That Adds Value to Melanoma Staging.

Authors:  Gerald Saldanha; Jeremy Yarrow; Jay Pancholi; Katarina Flatman; Kah Wee Teo; Somaia Elsheik; Rebecca Harrison; Marie O'Riordan; Mark Bamford
Journal:  Am J Surg Pathol       Date:  2018-06       Impact factor: 6.394

3.  Copper Chelation as Targeted Therapy in a Mouse Model of Oncogenic BRAF-Driven Papillary Thyroid Cancer.

Authors:  MengMeng Xu; Michael Casio; Danielle E Range; Julie A Sosa; Christopher M Counter
Journal:  Clin Cancer Res       Date:  2018-07-31       Impact factor: 13.801

Review 4.  HGF/c-MET Signaling in Melanocytes and Melanoma.

Authors:  Malgorzata Czyz
Journal:  Int J Mol Sci       Date:  2018-12-03       Impact factor: 5.923

Review 5.  Fibroblast Growth Factor Receptor Signaling in Skin Cancers.

Authors:  Malgorzata Czyz
Journal:  Cells       Date:  2019-06-04       Impact factor: 6.600

6.  Journey of the Patient With Melanoma: Understanding Resource Use and Bridging the Gap Between Dermatologist, Surgeon, and Oncologist in Different Health Care Systems.

Authors:  Cássia Rita Pereira da Veiga; Claudimar Pereira da Veiga; Ana Paula Drummond-Lage; Alberto Julius Alves Wainstein; Andreia Cristina de Melo
Journal:  J Glob Oncol       Date:  2019-07

7.  Long Noncoding RNA Taurine-Upregulated Gene1 (TUG1) Promotes Tumor Growth and Metastasis Through TUG1/Mir-129-5p/Astrocyte-Elevated Gene-1 (AEG-1) Axis in Malignant Melanoma.

Authors:  Jianwen Long; Qiqige Menggen; Qimige Wuren; Quan Shi; Xianming Pi
Journal:  Med Sci Monit       Date:  2018-03-15

8.  TERT Promoter Mutations Differently Correlate with the Clinical Outcome of MAPK Inhibitor-Treated Melanoma Patients.

Authors:  Paola Del Bianco; Camilla Stagni; Silvia Giunco; Alessio Fabozzi; Lisa Elefanti; Stefania Pellegrini; Antonella Vecchiato; Jacopo Pigozzo; Carolina Zamuner; Anita De Rossi; Arcangela De Nicolo; Chiara Menin
Journal:  Cancers (Basel)       Date:  2020-04-11       Impact factor: 6.639

Review 9.  The Evolution of Care of Cancers of the Head and Neck Region: State of the Science in 2020.

Authors:  Flora Yan; Hannah M Knochelmann; Patrick F Morgan; John M Kaczmar; David M Neskey; Evan M Graboyes; Shaun A Nguyen; Besim Ogretmen; Anand K Sharma; Terry A Day
Journal:  Cancers (Basel)       Date:  2020-06-11       Impact factor: 6.639

10.  Tissue-engineered 3D melanoma model with blood and lymphatic capillaries for drug development.

Authors:  Jennifer Bourland; Julie Fradette; François A Auger
Journal:  Sci Rep       Date:  2018-09-04       Impact factor: 4.379
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.